Benoît Pastour
Corporate Officer/Principal bij ALTUR INVESTISSEMENT
Profiel
Benoît Pastour is currently the Chief Executive Officer at Nord Capital Partenaires SAS since 2010.
He is also the Director at Aterovax SA since 2013.
In addition, he holds the position of Deputy Manager at Turenne Capital Partenaires SA since 2008.
Furthermore, he serves as the Executive Vice President at Altur Investissement SCA.
Mr. Pastour previously worked as the Director-Participations at Vauban Partenaires SA from 1991 to 2007.
He also held the position of Director at DNA Therapeutics SASU and Biom'Up SA. Additionally, he was the Head-LBO Financing at UniCredit SpA.
Mr. Pastour completed his graduate degree at Université Paris 1.
Panthéon-Sorbonne and IÉSEG School of Management.
Actieve functies van Benoît Pastour
| Bedrijven | Functie | Begin |
|---|---|---|
| ALTUR INVESTISSEMENT | Corporate Officer/Principal | 08-03-2011 |
Turenne Capital Partenaires SA
 Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France. | President | 14-04-2009 |
| Nord Capital Partenaires SAS | Algemeen Directeur | 12-11-2010 |
Aterovax SA
 Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Directeur/Bestuurslid | 03-09-2013 |
Eerdere bekende functies van Benoît Pastour
| Bedrijven | Functie | Einde |
|---|---|---|
Vauban Partenaires SA
 Vauban Partenaires SA Investment ManagersFinance Vauban Partenaires SA (VP) is an independent boutique-sized private equity firm established in 1992 and based in Paris. Crédit Agricole SA (XP: ACA) is a significant minority shareholder. The firm operates in close relationship with their majority-owned subsidiary Participex Gestion, based in Lille in northern France. Both firms manage private equity funds including regional development funds. Their clients are leading financial institutions, regional banks and insurance companies. Their lead investors are regional subsidiaries of Crédit Agricole. | Lid van de Investeringscommissie | 01-12-2007 |
| BIOM'UP | Directeur/Bestuurslid | - |
DNA Therapeutics SASU
 DNA Therapeutics SASU BiotechnologyHealth Technology DNA Therapeutics SA operates as a clinical stage biopharmaceutical company. It focuses in the research and development of life-saving therapeutics for treatment-resistant cancers. The company was founded by Jian-Sheng Sun and Marie Dutreix in June 2006 and is headquartered in Evry, France. | Directeur/Bestuurslid | - |
| UNICREDIT S.P.A. | Corporate Officer/Principal | - |
Opleiding van Benoît Pastour
| Université Paris 1 Panthéon-Sorbonne | Graduate Degree |
| IÉSEG School of Management | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| UNICREDIT S.P.A. | Finance |
| Bedrijven in privébezit | 7 |
|---|---|
Vauban Partenaires SA
Vauban Partenaires SA Investment ManagersFinance Vauban Partenaires SA (VP) is an independent boutique-sized private equity firm established in 1992 and based in Paris. Crédit Agricole SA (XP: ACA) is a significant minority shareholder. The firm operates in close relationship with their majority-owned subsidiary Participex Gestion, based in Lille in northern France. Both firms manage private equity funds including regional development funds. Their clients are leading financial institutions, regional banks and insurance companies. Their lead investors are regional subsidiaries of Crédit Agricole. | Finance |
Turenne Capital Partenaires SA
Turenne Capital Partenaires SA Investment ManagersFinance Turenne Capital Partenaires SA (Turenne Capital) is a venture capital subsidiary of Turenne Associés SA founded in 1999 by Aymard de Lasteyrie. The firm is headquartered in Paris, France. | Finance |
| Nord Capital Partenaires SAS | Finance |
Altur Investissement SCA
 Altur Investissement SCA Investment ManagersFinance Altur Investissement SCA acquires, invests and manages shares in private companies. Its portfolio includes health services, hotels, outsources services and specialized distribution. The company was founded by Francois Lombard on September 7, 2006 and is headquartered in Paris, France. | Finance |
DNA Therapeutics SASU
DNA Therapeutics SASU BiotechnologyHealth Technology DNA Therapeutics SA operates as a clinical stage biopharmaceutical company. It focuses in the research and development of life-saving therapeutics for treatment-resistant cancers. The company was founded by Jian-Sheng Sun and Marie Dutreix in June 2006 and is headquartered in Evry, France. | Health Technology |
Biom'Up SA
 Biom'Up SA Medical SpecialtiesHealth Technology Biom'Up SA engages in the development of hemostatic product composed of patent-protected biopolymers. Its products include Hemoblast Bellows and Hemosnow. The company was founded by Patricia Forest, Sylvain Picot and Christian Gagnieu on February 21, 2005 and is headquartered in Lyon, France. | Health Technology |
Aterovax SA
Aterovax SA Medical/Nursing ServicesHealth Services Aterovax SA develops in vitro diagnostic products for the management and assessment of cardiovascular diseases. Its products include diagnostic blood tests for determining and measuring activity of the cardiovascular biomarkers secretory phospholipase A2 (sPLA2) and secretory phospholipase A2-IIA (sPLA2-IIA) which provide physicians clinical information about the presence of a destabilized atherosclerotic plaque. The company was founded by Alain Tedgui, Ziad Mallat, Philippe Gabriel Steg, Joelle Benessiano and Jean-Marie Freyssinet on June 29, 2006 and is headquartered in Paris, France. | Health Services |
